NanoVibronix (NanoVibronix) Float Percentage Of Total Shares Outstanding : 73.28% (As of May. 03, 2024)

View and export this data going back to 2015. Start your Free Trial

What is NanoVibronix Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, NanoVibronix's float shares is 2.04 Mil. NanoVibronix's total shares outstanding is 2.78 Mil. NanoVibronix's float percentage of total shares outstanding is 73.28%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, NanoVibronix's Insider Ownership is 6.40%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, NanoVibronix's Institutional Ownership is 1.33%.

NanoVibronix Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

NanoVibronix's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	2.04	/	2.78
	=	73.28%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NanoVibronix (NanoVibronix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NanoVibronix Inc (NAS:NAOV) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

56R0:Germany

Address

525 Executive Boulevard, Elmsford, New York, NY, USA, 10523

Website

https://www.nanovibronix.com

NanoVibronix Inc manufactures noninvasive biological response-activating devices that target biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products are UroShield; PainShield; and WoundShield. Each of its UroShield, PainShield, and WoundShield products employs a small, disposable transducer that transmits low frequency, low intensity ultrasound acoustic waves that seek to repair and regenerate tissue, musculoskeletal and vascular structures, and decrease biofilm formation on urinary catheters and associated urinary tract infections. The company derives revenues from selling its products directly to patients as well as through distributor agreements.

Executives

Christopher M Fashek	director	8023 VANTAGE DR, SAN ANTONIO TX 78230
Stephen Russell Brown	officer: Chief Financial Officer	18-B NEIL COURT, OCEANSIDE NY 11572
Aurora Cassirer	director	C/O NANOVIBRONIX, INC.,, 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Maria Schroeder	director	C/O NANOVIBRONIX, INC.,, 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Brian M Murphy	director, officer: Chief Executive Officer	525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Michael Ferguson	director	525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Thomas Mika	director	TEGAL CORP, 2201 SOUTH MCDOWELL BLVD, PETALUMA CA 94954
Ira A Greenstein	director	IDT CORP, 520 BROAD STREET, NEWARK NJ 07102
Harold Jacob	director, officer: Chief Medical Officer	HAADMUR MEBUYON 26, HARNOT, JERUSALEM L3 95403
Martin M Goldstein	director	C/O NANOVIBRONIX, INC., 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
William Stern	director, officer: Chief Executive Officer	525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Jona Zumeris	director, officer: VP of Technology	105 MAXESS ROAD, SUITE S124, MELVILLE NY 11747
Miriam W Kelly	10 percent owner	P.O. BOX 1443, BROOKLANDVILLE MD 21022